Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast

Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast

PR Newswire

RICHMOND, Calif., July 16, 2013

RICHMOND, Calif., July 16, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc.
(Nasdaq: SGMO) today announced that the company will release its second
quarter 2013 financial results on Wednesday, July 24, 2013, after the market
closes. The press release will be followed by a conference call at 5:00 p.m.
ET, which will be open to the public via telephone and webcast. During the
conference call, the company will review the financial results and discuss
other business matters.


The conference call dial-in numbers are 877-377-7553 for domestic callers and
678-894-3968 for international callers. The passcode for the call is
11824773. Participants may access the live webcast via a link on the Sangamo
BioSciences website in the Investors section under "Events and Presentations" For those unable to listen in at the
designated time, a conference call replay will be available for one week
following the conference call, from approximately 8:00 p.m. ET on July 24,
2013 to 11:59 p.m. ET on July 31, 2013. The conference call replay numbers for
domestic and international callers are 855-859-2056 and 404-537-3406,
respectively. The conference ID number for the replay is 11824773.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel
DNA-binding proteins for therapeutic gene regulation and genome editing. It
has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and
efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's
other therapeutic programs are focused on monogenic diseases, including
hemophilia, Huntington's disease andhemoglobinopathies such as
beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable
the engineering of a class of DNA-binding proteins known as zinc finger
DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific
DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs)
for gene modification and ZFP transcription factors (ZFP TFs) that can control
gene expression and, consequently, cell function. Sangamo has entered into a
strategic collaboration with Shire to develop therapeutics for hemophilia,
Huntington's disease and other monogenic diseases and has established
strategic partnerships with companies in non-therapeutic applications of its
technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more
information about Sangamo, visit the company's website at

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.

Contact: Elizabeth Wolffe, Ph.D., Sangamo BioSciences, Inc., 510-970-6000,
Press spacebar to pause and continue. Press esc to stop.